Cardiff Oncology, Inc.
Key Metrics
Market Snapshot
About
Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel therapies for the treatment of cancer. Headquartered in San Diego, California, the company's lead product candidate is onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor being evaluated in combination with standard-of-care chemotherapy across multiple cancer types. Cardiff is conducting clinical trials in colorectal cancer, KRAS-mutated metastatic colorectal cancer, and other solid tumors. The company's research focuses on targeting cancer cell proliferation and resistance mechanisms.